House of Lords Business
Show full summary

Baroness Altmann to ask His Majesty's Government, further to the finding from the National Institute for Health and Care Excellence (NICE) that "Evusheld is not recommended for vulnerable adults who are at high risk of severe COVID-19 because there is not enough evidence of its effectiveness against current variants and those likely to be circulating in the next 6 months", what consideration they have given to using human-derived convalescent plasma for immune compromised individuals; and what trials they have undertaken, if any, to test its effectiveness.  HL5825

Question HL5825: tabled on 23 February 2023 and due for answer by 9 March 2023

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Baroness Altmann to ask His Majesty's Government, further to the finding from the National Institute for Health and Care Excellence (NICE) that "Evusheld is not recommended for vulnerable adults who are at high risk of severe COVID-19 because there is not enough evidence of its effectiveness against current variants and those likely to be circulating in the next 6 months", what consideration they have given to using human-derived convalescent plasma for immune compromised individuals; and what trials they have undertaken, if any, to test its effectiveness.  HL5825
Legend for business item text
† Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

Baroness Altmann
Non-affiliated
Life peer